Argenica Therapeutics Ltd has released a press release.
Phase 2 Trial Promising Improvements in Functional Outcomes
Filed with ASX ·
6ix hasn’t read this filing yet.
Argenica Therapeutics Ltd on 6ix
Earlier from Argenica Therapeutics
- Topline Phase 2 Trial Results of ARG-007 in AIS Patients
- Trading Halt
- Appendix 4E & Annual Report to 30 June 2025
- Argenica Receives IND Feedback From FDA
- Argenica Awarded Federal Government Funding
Later from Argenica Therapeutics
- ARG-007 Efficacious Dose Validated in New Preclinical Study
- Positive TNK Study Results Fulfil Key FDA Requirement
- AI Analysis Reveals Efficacy In Severe Stroke Patients
- Quarterly Activities/Appendix 4C Cash Flow Report
- Successful Applicaton for EMA Paediatric Waiver
Follow Argenica Therapeutics into a list and get an email when it puts out news.
Follow Argenica Therapeutics